US equities
|
SPCX
$171.09
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
SKHY
$195.02
▲+0.00%
SNDK
$1,704.16
▲+0.00%
TSLA
$378.73
▲+0.00%
INTC
$116.19
▲+0.00%
SDEV
$3.94
▲+0.00%
SPCX
$171.09
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
SKHY
$195.02
▲+0.00%
SNDK
$1,704.16
▲+0.00%
TSLA
$378.73
▲+0.00%
INTC
$116.19
▲+0.00%
SDEV
$3.94
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Biomark Diagnostics Inc
(CSE:
BUX
)
0.5500
-0.0100 (-1.79%)
Delayed Quote
Updated: 3:59 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomark Diagnostics Inc
< Previous
1
2
Next >
BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
September 21, 2026
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or...
Via
Newsfile
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
August 25, 2026
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...
Via
Newsfile
Topics
Artificial Intelligence
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
July 31, 2026
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - As the global healthcare community unites on August 1st to observe...
Via
Newsfile
Topics
Death
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
June 23, 2026
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...
Via
Newsfile
Topics
Intellectual Property
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
June 09, 2026
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...
Via
Newsfile
Topics
Intellectual Property
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
April 14, 2026
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...
Via
Newsfile
Topics
Death
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
January 15, 2026
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a...
Via
Newsfile
Topics
Artificial Intelligence
BioMark: 2025 Achievements & 2026 Vision
December 31, 2025
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...
Via
Newsfile
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
December 30, 2025
Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...
Via
Newsfile
Topics
Artificial Intelligence
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
December 23, 2025
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading...
Via
Newsfile
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
December 01, 2025
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a...
Via
Newsfile
Topics
Artificial Intelligence
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
November 12, 2025
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX)...
Via
Newsfile
Topics
Artificial Intelligence
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
October 07, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer...
Via
Newsfile
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
September 29, 2025
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading...
Via
Newsfile
Topics
Intellectual Property
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
August 12, 2025
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer...
Via
Newsfile
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement
December 29, 2023
Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"...
Via
Newsfile
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
December 04, 2023
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF)...
Via
Newsfile
Topics
Intellectual Property
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
November 28, 2023
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"...
Via
Newsfile
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
November 14, 2023
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...
Via
Newsfile
Topics
Artificial Intelligence
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test
November 07, 2023
Vancouver, British Columbia and Quebec City, Quebec--(Newsfile Corp. - November 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B)...
Via
Newsfile
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
October 24, 2023
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...
Via
Newsfile
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
August 30, 2023
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ...
Via
Newsfile
Topics
Intellectual Property
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
August 08, 2023
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"),...
Via
Newsfile
Topics
Intellectual Property
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting
June 05, 2023
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ...
Via
Newsfile
BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay
May 31, 2023
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...
Via
Newsfile
Topics
Death
Intellectual Property
BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
May 03, 2023
Vancouver, British Columbia--(Newsfile Corp. - May 3, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...
Via
Newsfile
BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors
March 16, 2023
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...
Via
Newsfile
Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring
February 07, 2023
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF)...
Via
Newsfile
BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch
January 11, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or...
Via
Newsfile
Topics
Climate Change
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
November 30, 2021
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...
Via
Newsfile
Topics
Artificial Intelligence
Death
< Previous
1
2
Next >
